Statin Intolerance: an Overview of the Current Status and Possible Treatment Options
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Lowering serum low-density lipoprotein cholesterol (LDL-C) is the mainstay for reduction of risk of cardiovascular disease (CVD), the second most common cause of death in Korea. The 2015 Korean guidelines for management of dyslipidemia strongly recommend the use of statins in patients at risk of CVD. Statin therapy, which is the gold standard for CVD, reduces LDL-C level by 40% to 60% and is generally well tolerated. However, many patients are intolerant to statins and discontinue therapy or become nonadherent to therapy because of actual/perceived side effects. The most common of these side effects is the statin-associated muscle symptom (SAMS). Discontinuation and repetitive re-challenge with statins can help identify SAMS. If serum creatinine kinase level is more than 10 times the upper limit of normal, statin therapy must be stopped immediately, and the physician should identify possible causes including rhabdomyolysis and treat appropriately. In other patients, it might help to switch to a less potent statin or to use statins at intermittent non-daily dosing. To achieve target LDL-C level, non-statin lipid-lowering therapies such as dietary modifications, ezetimibe, and bile acid sequestrants may be added. Several new drugs have recently been approved for lowering LDL-C level. Alirocumab and evolocumab are monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9, and both drugs cause large reductions in LDL-C, similar to statins. Lomitapide and mipomersen are orphan drugs used as adjuncts to other lipid-lowering therapies in patients with homozygous familial hypercholesterolemia.
Abstract
Lowering serum low-density lipoprotein cholesterol (LDL-C) is the mainstay for reduction of risk of cardiovascular disease (CVD), the second most common cause of death in Korea. The 2015 Korean guidelines for management of dyslipidemia strongly recommend the use of statins in patients at risk of CVD. Statin therapy, which is the gold standard for CVD, reduces LDL-C level by 40% to 60% and is generally well tolerated. However, many patients are intolerant to statins and discontinue therapy or become nonadherent to therapy because of actual/perceived side effects. The most common of these side effects is the statin-associated muscle symptom (SAMS). Discontinuation and repetitive re-challenge with statins can help identify SAMS. If serum creatinine kinase level is more than 10 times the upper limit of normal, statin therapy must be stopped immediately, and the physician should identify possible causes including rhabdomyolysis and treat appropriately. In other patients, it might help to switch to a less potent statin or to use statins at intermittent non-daily dosing. To achieve target LDL-C level, non-statin lipid-lowering therapies such as dietary modifications, ezetimibe, and bile acid sequestrants may be added. Several new drugs have recently been approved for lowering LDL-C level. Alirocumab and evolocumab are monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9, and both drugs cause large reductions in LDL-C, similar to statins. Lomitapide and mipomersen are orphan drugs used as adjuncts to other lipid-lowering therapies in patients with homozygous familial hypercholesterolemia.
참고문헌 (48)
- Committee for the Korean Guidelines for the Management of Dyslipidemia, "2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation)", Korean Circulation Journal, 46(3), pp.275~306 (2016), 대한심장학회[DOI]
- 통계청 인구동향과, "Cause-of-death statistics in 2016 in the Republic of Korea", 대한의사협회지, 61(9), pp.573~584 (2018), 대한의사협회[DOI]
- Cholesterol Treatment Trialists' (CTT) Collaborators, "The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials", Lancet, 380, pp.581~590 (2012)
- Kim SH, "Assessment of the efficacy and tolerability of 2 formulations of atorvastatin in Korean adults with hypercholesterolemia: a multicenter, prospective, open-label, randomized trial", Clin Ther, 35, pp.77~86 (2013)
- Stroes ES, "Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management", Eur Heart J, 36, pp.1012~1022 (2015)
- Cho YE, "Integrative analysis of proteomic and transcriptomic data for identification of pathways related to simvastatin-induced hepatotoxicity", Proteomics, 13, pp.1257~1275 (2013)
- Endo A, "A historical perspective on the discovery of statins", Proc Jpn Acad Ser B Phys Biol Sci, 86, pp.484~493 (2010)
- Young SG, "Lowering plasma cholesterol by raising LDL receptors--revisited", N Engl J Med, 366, pp.1154~1155 (2012)
- Enas EA, "Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes", Indian J Med Res, 138, pp.461~491 (2013)
- Khang AR, "Comparison of different statin therapy to change low-density lipoprotein cholesterol and high-density lipoprotein cholesterol level in Korean patients with and without diabetes", J Clin Lipidol, 10, pp.528~537.e3 (2016)
- Brautbar A, "Pharmacological strategies for lowering LDL cholesterol: statins and beyond", Nat Rev Cardiol, 8, pp.253~265 (2011)
- Fitchett DH, "Cardiology patient page. Statin intolerance", Circulation, 131, pp.e389~e391 (2015)
- Banach M, "Statin intolerance - an attempt at a unified definition. Position paper from an international lipid expert panel", Arch Med Sci, 11, pp.1~23 (2015)
- Gulizia MM, "ANMCO position paper: diagnostic-therapeutic pathway in patients with hypercholesterolaemia and statin intolerance", Eur Heart J Suppl, 19(Suppl D), pp.D55~D63 (2017)
- Guyton JR, "An assessment by the statin intolerance panel: 2014 update", J Clin Lipidol, 8(Suppl), pp.S72~S81 (2014)
- Harrison TN, "Unmet patient need in statin intolerance: the clinical characteristics and management", Cardiovasc Drugs Ther, 32, pp.29~36 (2018)
- Furberg CD, "Withdrawal of cerivastatin from the world market", Curr Control Trials Cardiovasc Med, 2, pp.205~207 (2001)
- Raju SB, "Management of statin intolerance", Indian J Endocrinol Metab, 17, pp.977~982 (2013)
- Sikka P, "Statin intolerance: now a solved problem", J Postgrad Med, 57, pp.321~328 (2011)
- Bitzur R, "Intolerance to statins: mechanisms and management", Diabetes Care, 36(Suppl 2), pp.S325~S330 (2013)
- Gluba-Brzozka A, "Molecular mechanisms of statin intolerance", Arch Med Sci, 12, pp.645~658 (2016)
- Kajinami K, "Management of patients with statin intolerance in Japan, South Korea and Taiwan: comparison of results from a clinician survey", Value in Health, 19, pp.A872~ (2016)
- Arca M, "Treating statin-intolerant patients", Diabetes Metab Syndr Obes, 4, pp.155~166 (2011)
- Stulc T, "Statin intolerance: the clinician's perspective", Curr Atheroscler Rep, 17, pp.69~ (2015)
- Bohula EA, "Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT", Circulation, 132, pp.1224~1233 (2015)
- Keene D, "Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients", BMJ, 349, pp.g4379~ (2014)
- Ip CK, "Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: a meta-analysis of randomized controlled trials", Int J Cardiol, 191, pp.138~148 (2015)
- AIM-HIGH Investigators, "Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy", N Engl J Med, 365, pp.2255~2267 (2011)
- Agouridis AP, "Strategies to overcome statin intolerance", Expert Opin Drug Metab Toxicol, 11, pp.851~855 (2015)
- "Regeneron announce approval of Praluent® (alirocumab) for the treatment of hypercholesterolemia in Japan" (2016)[URL]
- "Amgen's Repatha® (evolocumab) approved as first PCSK9 inhibitor in Japan for the treatment of high cholesterol" (2016)[URL]
- McDonagh M, "A systematic review of PCSK9 inhibitors alirocumab and evolocumab", J Manag Care Spec Pharm, 22, pp.641~653q (2016)
- Grundy SM, "Dyslipidaemia in 2015: advances in treatment of dyslipidaemia", Nat Rev Cardiol, 13, pp.74~75 (2016)
- Stein EA, "Effect of a monoclonal antibody to PCSK9 on LDL cholesterol", N Engl J Med, 366, pp.1108~1118 (2012)
- Stein EA, "Effect of a monoclonal antibody to PCSK9, REGN727", SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial, 2012, pp.380, 29~36
- Moriarty PM, "Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial", J Clin Lipidol, 9, pp.758~769 (2015)
- Sullivan D, "Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial", JAMA, 308, pp.2497~2506 (2012)
- Nissen SE, "Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial", JAMA, 315, pp.1580~1590 (2016)
- Blom DJ, "A 52-week placebo-controlled trial of evolocumab in hyperlipidemia", N Engl J Med, 370, pp.1809~1819 (2014)
- Robinson JG, "Efficacy and safety of alirocumab in reducing lipids and cardiovascular events", N Engl J Med, 372, pp.1489~1499 (2015)
- Sabatine MS, "Evolocumab and clinical outcomes in patients with cardiovascular disease", N Engl J Med, 376, pp.1713~1722 (2017)
- Rader DJ, "Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia", Circulation, 129, pp.1022~1032 (2014)
- Stefanutti C, "The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a phase 3, single-arm, open-label trial", Atherosclerosis, 240, pp.408~414 (2015)
- Turner T, "Non-statin treatments for managing LDL cholesterol and their outcomes", Clin Ther, 37, pp.2751~2769 (2015)
- Ray KK, "Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol", N Engl J Med, 376, pp.1430~1440 (2017)
- HPS3, "TIMI55–REVEAL Collaborative Group", Effects of anacetrapib in patients with atherosclerotic vascular disease, 2017, pp.377, 1217~1227
- Lincoff AM, "Evacetrapib and cardiovascular outcomes in high-risk vascular disease", N Engl J Med, 376, pp.1933~1942 (2017)
- Thompson PD, "Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance", J Clin Lipidol, 10, pp.556~567 (2016)